These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 39122901)

  • 1. Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing.
    de Taeye SW; Schriek AI; Umotoy JC; Grobben M; Burger JA; Sanders RW; Vidarsson G; Wuhrer M; Falck D; Kootstra NA; van Gils MJ
    Commun Biol; 2024 Aug; 7(1):964. PubMed ID: 39122901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells.
    Anand SP; Ding S; Tolbert WD; Prévost J; Richard J; Gil HM; Gendron-Lepage G; Cheung WF; Wang H; Pastora R; Saxena H; Wakarchuk W; Medjahed H; Wines BD; Hogarth M; Shaw GM; Martin MA; Burton DR; Hangartner L; Evans DT; Pazgier M; Cossar D; McLean MD; Finzi A
    J Virol; 2021 Aug; 95(18):e0079621. PubMed ID: 34232070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
    Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
    J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of anti-HIV-1 broadly neutralizing monoclonal antibodies with increased affinity to Fcγ receptors during acute SHIV
    Dias J; Fabozzi G; Fourati S; Chen X; Liu C; Ambrozak DR; Ransier A; Laboune F; Hu J; Shi W; March K; Maximova AA; Schmidt SD; Samsel J; Talana CA; Ernste K; Ko SH; Lucas ME; Radecki PE; Boswell KL; Nishimura Y; Todd JP; Martin MA; Petrovas C; Boritz EA; Doria-Rose NA; Douek DC; Sékaly RP; Lifson JD; Asokan M; Gama L; Mascola JR; Pegu A; Koup RA
    Nat Commun; 2024 Aug; 15(1):7461. PubMed ID: 39198422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.
    Tuyishime M; Garrido C; Jha S; Moeser M; Mielke D; LaBranche C; Montefiori D; Haynes BF; Joseph S; Margolis DM; Ferrari G
    J Clin Invest; 2020 Oct; 130(10):5157-5170. PubMed ID: 32584790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the predominant human NK cell effector subset mediating ADCC against HIV-infected targets coated with BNAbs or plasma from PLWH.
    Tomescu C; Kroll K; Colon K; Papasavvas E; Frank I; Tebas P; Mounzer K; Reeves RK; Montaner LJ
    Eur J Immunol; 2021 Aug; 51(8):2051-2061. PubMed ID: 34086344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
    Mujib S; Liu J; Rahman AKMN; Schwartz JA; Bonner P; Yue FY; Ostrowski MA
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
    McGuire AT; Glenn JA; Lippy A; Stamatatos L
    J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functions.
    Schriek AI; Falck D; Wuhrer M; Kootstra NA; van Gils MJ; de Taeye SW
    Antiviral Res; 2024 Nov; 231():106015. PubMed ID: 39343065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing the Relationship Between Neutralization Sensitivity and
    Wilson A; Shakhtour L; Ward A; Ren Y; Recarey M; Stevenson E; Korom M; Kovacs C; Benko E; Jones RB; Lynch RM
    Front Immunol; 2021; 12():710327. PubMed ID: 34603284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
    Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL
    Front Immunol; 2021; 12():733958. PubMed ID: 34566999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies.
    Parsons MS; Chung AW; Kent SJ
    Retrovirology; 2018 Aug; 15(1):58. PubMed ID: 30134945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells.
    Dufloo J; Planchais C; Frémont S; Lorin V; Guivel-Benhassine F; Stefic K; Casartelli N; Echard A; Roingeard P; Mouquet H; Schwartz O; Bruel T
    Nat Commun; 2022 Feb; 13(1):630. PubMed ID: 35110562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo sensitivity to broadly neutralizing antibodies and anti-CD4 antibody UB-421 of infectious viral isolates from people living with multidrug-resistant HIV.
    Rai MA; Blazkova J; Justement JS; Shi V; Kennedy BD; Manning MR; McLaughlin M; Sneller MC; Pau AK; Moir S; Chun TW
    EBioMedicine; 2024 Jun; 104():105151. PubMed ID: 38728839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
    Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity.
    Mayr LM; Decoville T; Schmidt S; Laumond G; Klingler J; Ducloy C; Bahram S; Zolla-Pazner S; Moog C
    Sci Rep; 2017 Oct; 7(1):12655. PubMed ID: 28978939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies.
    Boutin M; Vézina D; Ding S; Prévost J; Laumaea A; Marchitto L; Anand SP; Medjahed H; Gendron-Lepage G; Bourassa C; Goyette G; Clark A; Richard J; Finzi A
    mBio; 2022 Jun; 13(3):e0057722. PubMed ID: 35475646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
    Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.